BTIG Research Reaffirms Buy Rating for Avalo Therapeutics (NASDAQ:AVTX)

Avalo Therapeutics (NASDAQ:AVTX)‘s stock had its “buy” rating reaffirmed by equities researchers at BTIG Research in a research report issued on Tuesday,Benzinga reports. They presently have a $40.00 target price on the stock. BTIG Research’s price target indicates a potential upside of 186.74% from the company’s previous close.

A number of other equities research analysts have also recently commented on the company. Mizuho upgraded Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Guggenheim assumed coverage on Avalo Therapeutics in a report on Monday, February 2nd. They issued a “buy” rating and a $50.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Friday, January 9th. Finally, HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of Avalo Therapeutics in a research report on Thursday, January 15th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $42.25.

Avalo Therapeutics Price Performance

AVTX opened at $13.95 on Tuesday. The stock has a market cap of $317.92 million, a P/E ratio of -2.43 and a beta of 0.84. The firm has a fifty day moving average price of $15.53 and a 200 day moving average price of $15.77. Avalo Therapeutics has a 1 year low of $3.39 and a 1 year high of $20.72.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.54) by $1.17. The firm had revenue of $0.06 million during the quarter. Equities analysts expect that Avalo Therapeutics will post -19.07 EPS for the current year.

Insider Activity at Avalo Therapeutics

In related news, insider Mittie Doyle sold 25,492 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $16.15, for a total transaction of $411,695.80. Following the completion of the transaction, the insider owned 3,622 shares in the company, valued at $58,495.30. This represents a 87.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 3.03% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Avalo Therapeutics

Institutional investors have recently bought and sold shares of the company. BIT Capital GmbH acquired a new position in shares of Avalo Therapeutics during the third quarter valued at approximately $25,000. PFS Partners LLC boosted its stake in shares of Avalo Therapeutics by 100.0% in the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock worth $36,000 after acquiring an additional 1,000 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in shares of Avalo Therapeutics in the second quarter worth approximately $55,000. Dimensional Fund Advisors LP purchased a new stake in shares of Avalo Therapeutics during the third quarter worth approximately $143,000. Finally, Boothbay Fund Management LLC purchased a new stake in shares of Avalo Therapeutics during the second quarter worth approximately $56,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.